Business UpdateJul 6, 2026, 09:02 AM
MIRA Pharma Reports Positive Preclinical Results for SKNY-1
AI Summary
MIRA Pharmaceuticals announced positive preclinical study results for SKNY-1, its oral drug candidate for obesity and addiction-related disorders. The studies demonstrated favorable oral bioavailability, reproducible systemic exposure, robust brain penetration, and substantial liver exposure, supporting potential once-daily oral dosing. These findings strengthen SKNY-1's development profile, complementing previous efficacy studies that showed reductions in body weight and attenuation of compulsive behaviors without anxiety-related side effects.
Key Highlights
- SKNY-1 optimized oral formulation showed favorable oral bioavailability.
- Studies demonstrated robust brain penetration and substantial liver exposure.
- Pharmacokinetic profile supports potential for convenient once-daily oral dosing.
- SKNY-1 did not produce anxiety-related behavioral effects in preclinical models.
- Findings complement prior efficacy data on weight reduction and metabolic improvements.
- SKNY-1 features biased CB1 receptor modulation, partial CB2 agonism, and selective MAO-B inhibition.
Price Impact
More from MIRA